E
Biostax Corp.
BTAX
$0.01
$0.00111.11%
E
Sell
7/15/2024Upgraded
Biostax Corp. (BTAX) was upgraded to E+ from E on 7/15/2024 due to an increase in the volatility index.
Biostax Corp. (BTAX) was upgraded to E+ from E on 7/15/2024 due to an increase in the volatility index.
E
Sell
6/28/2024Downgrade
Biostax Corp. (BTAX) was downgraded to E from E+ on 6/28/2024 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 0.01 to 0, and debt to equity increased from -0.31 to -0.26.
Biostax Corp. (BTAX) was downgraded to E from E+ on 6/28/2024 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 0.01 to 0, and debt to equity increased from -0.31 to -0.26.
E
Sell
11/21/2023Upgraded
Biostax Corp. (BTAX) was upgraded to E+ from E on 11/21/2023 due to a major increase in the growth index and efficiency index. Operating cash flow increased 103.54% from -$314 to $11.1, earnings per share increased from -$0.0061 to -$0.0047, and net income increased 22.89% from -$504.2 to -$388.8.
Biostax Corp. (BTAX) was upgraded to E+ from E on 11/21/2023 due to a major increase in the growth index and efficiency index. Operating cash flow increased 103.54% from -$314 to $11.1, earnings per share increased from -$0.0061 to -$0.0047, and net income increased 22.89% from -$504.2 to -$388.8.
E
Sell
4/11/2023Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to E from E+ on 4/11/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.07 to 0.04.
Immune Therapeutics, Inc. (IMUN) was downgraded to E from E+ on 4/11/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.07 to 0.04.
E
Sell
11/21/2022Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to E+ from D on 11/21/2022 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 239.08% from $1.79M to -$2.49M, earnings per share declined from $0.23 to -$0.0415, and EBIT declined 44.09% from -$292.1 to -$420.9.
Immune Therapeutics, Inc. (IMUN) was downgraded to E+ from D on 11/21/2022 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 239.08% from $1.79M to -$2.49M, earnings per share declined from $0.23 to -$0.0415, and EBIT declined 44.09% from -$292.1 to -$420.9.
D
Sell
8/11/2021Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 8/11/2021 due to a noticeable decline in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 8/11/2021 due to a noticeable decline in the total return index and volatility index.
D
Sell
6/18/2021Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D+ from C- on 6/18/2021 due to a noticeable decline in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D+ from C- on 6/18/2021 due to a noticeable decline in the total return index and volatility index.
C
Hold
5/26/2021Upgraded
Immune Therapeutics, Inc. (IMUND) was upgraded to C- from D on 5/26/2021 due to a substantial increase in the growth index and valuation index. Operating cash flow increased 105.67% from -$30 to $1.7, and EBIT increased 16.14% from -$342.7 to -$287.4.
Immune Therapeutics, Inc. (IMUND) was upgraded to C- from D on 5/26/2021 due to a substantial increase in the growth index and valuation index. Operating cash flow increased 105.67% from -$30 to $1.7, and EBIT increased 16.14% from -$342.7 to -$287.4.
D
Sell
4/16/2021Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 4/16/2021 due to a major decline in the growth index and total return index. EBIT declined 161.6% from -$131 to -$342.7, and earnings per share declined from $0.0089 to -$0.0019.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 4/16/2021 due to a major decline in the growth index and total return index. EBIT declined 161.6% from -$131 to -$342.7, and earnings per share declined from $0.0089 to -$0.0019.
D
Sell
12/18/2020Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 12/18/2020 due to a noticeable increase in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 12/18/2020 due to a noticeable increase in the total return index and volatility index.
D
Sell
12/3/2020Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 12/3/2020 due to a decline in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 12/3/2020 due to a decline in the total return index and volatility index.
D
Sell
11/18/2020Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 11/18/2020 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 609.57% from -$803.5 to $4.09M, and total capital increased 14.48% from -$9.7M to -$8.3M.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 11/18/2020 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 609.57% from -$803.5 to $4.09M, and total capital increased 14.48% from -$9.7M to -$8.3M.
D
Sell
6/2/2020Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index and total return index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index and total return index.
D
Sell
5/15/2020Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D- from D on 5/15/2020 due to a significant decline in the efficiency index and growth index. Earnings per share declined from -$0.0021 to -$7.4179, EBIT declined 245.48% from -$389.2 to -$1.34M, and total capital declined 3.89% from -$7.84M to -$8.14M.
Immune Therapeutics, Inc. (IMUN) was downgraded to D- from D on 5/15/2020 due to a significant decline in the efficiency index and growth index. Earnings per share declined from -$0.0021 to -$7.4179, EBIT declined 245.48% from -$389.2 to -$1.34M, and total capital declined 3.89% from -$7.84M to -$8.14M.
D
Sell
4/15/2020Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from C- on 4/15/2020 due to a significant decline in the solvency index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from C- on 4/15/2020 due to a significant decline in the solvency index.
C
Hold
4/3/2020Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to C- from D+ on 4/3/2020 due to an increase in the volatility index and total return index.
Immune Therapeutics, Inc. (IMUN) was upgraded to C- from D+ on 4/3/2020 due to an increase in the volatility index and total return index.
D
Sell
12/5/2019Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 12/5/2019 due to a noticeable increase in the growth index and total return index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 12/5/2019 due to a noticeable increase in the growth index and total return index.
D
Sell
11/20/2019Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 11/20/2019 due to a noticeable decline in the growth index. Earnings per share declined from -$0.0018 to -$2.0666, and operating cash flow declined 194.9% from $15.7 to -$14.9.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 11/20/2019 due to a noticeable decline in the growth index. Earnings per share declined from -$0.0018 to -$2.0666, and operating cash flow declined 194.9% from $15.7 to -$14.9.
D
Sell
9/6/2019Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 9/6/2019 due to an increase in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 9/6/2019 due to an increase in the total return index and volatility index.
D
Sell
7/25/2019Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 7/25/2019 due to a decline in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 7/25/2019 due to a decline in the total return index and volatility index.
D
Sell
7/10/2019Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 7/10/2019 due to an increase in the efficiency index, total return index and growth index. Operating cash flow increased 99.96% from -$444.6 to -$200, EBIT increased 30.04% from -$867.7 to -$607, and net income increased 24.82% from -$943.6 to -$709.4.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 7/10/2019 due to an increase in the efficiency index, total return index and growth index. Operating cash flow increased 99.96% from -$444.6 to -$200, EBIT increased 30.04% from -$867.7 to -$607, and net income increased 24.82% from -$943.6 to -$709.4.
D
Sell
9/27/2018Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 9/27/2018 due to a decline in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 9/27/2018 due to a decline in the total return index and volatility index.
D
Sell
8/31/2018Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 8/31/2018 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 13.23% from -$5.99M to -$5.2M.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 8/31/2018 due to an increase in the efficiency index, total return index and volatility index. Total capital increased 13.23% from -$5.99M to -$5.2M.
D
Sell
8/14/2018Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 8/14/2018 due to a decline in the total return index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 8/14/2018 due to a decline in the total return index.
D
Sell
7/26/2018Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 7/26/2018 due to an increase in the total return index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 7/26/2018 due to an increase in the total return index.
D
Sell
7/11/2018Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 7/11/2018 due to a decline in the total return index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 7/11/2018 due to a decline in the total return index.
D
Sell
4/4/2018Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 4/4/2018 due to a significant increase in the efficiency index, total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 4/4/2018 due to a significant increase in the efficiency index, total return index and volatility index.
D
Sell
12/26/2017Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D from D- on 12/26/2017 due to an increase in the volatility index, total return index and valuation index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D from D- on 12/26/2017 due to an increase in the volatility index, total return index and valuation index.
D
Sell
12/11/2017Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D- from D on 12/11/2017 due to a decline in the total return index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D- from D on 12/11/2017 due to a decline in the total return index.
D
Sell
5/12/2017Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D from D- on 5/12/2017 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0209 to -$0.0099, and EBIT increased 23.41% from -$1.98M to -$1.52M.
Immune Therapeutics, Inc. (IMUN) was upgraded to D from D- on 5/12/2017 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0209 to -$0.0099, and EBIT increased 23.41% from -$1.98M to -$1.52M.
D
Sell
4/4/2017Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D- from D on 4/4/2017 due to a significant decline in the efficiency index, growth index and total return index. Net income declined 28.41% from -$3.94M to -$5.05M, total capital declined 25.9% from -$3.89M to -$4.9M, and earnings per share declined from -$0.0174 to -$0.0209.
Immune Therapeutics, Inc. (IMUN) was downgraded to D- from D on 4/4/2017 due to a significant decline in the efficiency index, growth index and total return index. Net income declined 28.41% from -$3.94M to -$5.05M, total capital declined 25.9% from -$3.89M to -$4.9M, and earnings per share declined from -$0.0174 to -$0.0209.
D
Sell
11/11/2016Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 11/11/2016 due to a major decline in the total return index and volatility index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 11/11/2016 due to a major decline in the total return index and volatility index.
D
Sell
8/16/2016Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D+ from C- on 8/16/2016 due to a noticeable decline in the growth index and total return index. Operating cash flow declined 34.08% from -$598 to -$801.8.
Immune Therapeutics, Inc. (IMUN) was downgraded to D+ from C- on 8/16/2016 due to a noticeable decline in the growth index and total return index. Operating cash flow declined 34.08% from -$598 to -$801.8.
C
Hold
5/18/2016Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to C- from D+ on 5/18/2016 due to a large increase in the growth index and valuation index. Operating cash flow increased 35.61% from -$928.7 to -$598, and earnings per share increased from -$0.0424 to -$0.0346.
Immune Therapeutics, Inc. (IMUN) was upgraded to C- from D+ on 5/18/2016 due to a large increase in the growth index and valuation index. Operating cash flow increased 35.61% from -$928.7 to -$598, and earnings per share increased from -$0.0424 to -$0.0346.
D
Sell
4/1/2016Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 4/1/2016 due to a significant increase in the efficiency index, valuation index and growth index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 4/1/2016 due to a significant increase in the efficiency index, valuation index and growth index.
D
Sell
3/4/2016Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 3/4/2016 due to a decline in the total return index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 3/4/2016 due to a decline in the total return index.
D
Sell
2/18/2016Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 2/18/2016 due to a large increase in the total return index and valuation index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 2/18/2016 due to a large increase in the total return index and valuation index.
D
Sell
1/15/2016Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 1/15/2016 due to a large decline in the total return index.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 1/15/2016 due to a large decline in the total return index.
D
Sell
12/31/2015Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 12/31/2015 due to a large increase in the total return index.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 12/31/2015 due to a large increase in the total return index.
D
Sell
11/17/2015Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 11/17/2015 due to a major decline in the growth index, total return index and solvency index. Debt to equity increased from 1.66 to 2.43, and total revenue declined 10.71% from $5.6 to $5.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 11/17/2015 due to a major decline in the growth index, total return index and solvency index. Debt to equity increased from 1.66 to 2.43, and total revenue declined 10.71% from $5.6 to $5.
D
Sell
8/14/2015Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 8/14/2015 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 166.67% from $2.1 to $5.6.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 8/14/2015 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 166.67% from $2.1 to $5.6.
D
Sell
5/15/2015Downgrade
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 5/15/2015 due to a decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.29 to 0.83, the quick ratio declined from 0.06 to 0.01, and earnings per share declined from -$0.0981 to -$0.02.
Immune Therapeutics, Inc. (IMUN) was downgraded to D from D+ on 5/15/2015 due to a decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.29 to 0.83, the quick ratio declined from 0.06 to 0.01, and earnings per share declined from -$0.0981 to -$0.02.
D
Sell
4/2/2015Upgraded
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 4/2/2015 due to a major increase in the growth index and valuation index. Operating cash flow increased 42.67% from -$528.5 to -$754.
Immune Therapeutics, Inc. (IMUN) was upgraded to D+ from D on 4/2/2015 due to a major increase in the growth index and valuation index. Operating cash flow increased 42.67% from -$528.5 to -$754.
OTC PK
01/14/2025 2:21PM Eastern
Quotes delayed
